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Plant tumour biocontrol agent employs
a tRNA-dependent mechanism to inhibit
leucyl-tRNA synthetase
Shaileja Chopra1,*, Andrés Palencia2,*, Cornelia Virus1, Ashutosh Tripathy3, Brenda R. Temple4,
Adrian Velazquez-Campoy5, Stephen Cusack2 & John S. Reader1
Leucyl-tRNA synthetases (LeuRSs) have an essential role in translation and are promising
targets for antibiotic development. Agrocin 84 is a LeuRS inhibitor produced by the biocontrol
agent Agrobacterium radiobacter K84 that targets pathogenic strains of A. tumefaciens, the
causative agent of plant tumours. Agrocin 84 acts as a molecular Trojan horse and is pro-
cessed inside the pathogen into a toxic moiety (TM84). Here we show using crystal struc-
ture, thermodynamic and kinetic analyses, that this natural antibiotic employs a unique and
previously undescribed mechanism to inhibit LeuRS. TM84 requires tRNALeu for tight binding
to the LeuRS synthetic active site, unlike any previously reported inhibitors. TM84 traps the
enzyme–tRNA complex in a novel ‘aminoacylation-like’ conformation, forming novel inter-
actions with the KMSKS loop and the tRNA 30-end. Our findings reveal an intriguing tRNA-
dependent inhibition mechanism that may confer a distinct evolutionary advantage in vivo and
inform future rational antibiotic design.
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L
eucyl-tRNA synthetases (LeuRSs) have an essential role in
translating the genetic code by ligating leucine (Leu) to the
30-end of tRNALeu. The LeuRS aminoacylation reaction is
catalysed by a highly conserved catalytic domain encoding a
nucleotide-binding Rossman fold, and the class I aminoacyl-
tRNA synthetase (aaRS)-defining catalytic peptide sequences, the
HIGH and KMSKS motifs1,2. The reaction is catalysed in a two-
step mechanism (Fig. 1a): in the tRNA-independent first step, Leu
is activated by ATP to form a tightly-bound high-energy
intermediate Leu-AMP and release of inorganic pyrophosphate;
in the second step, Leu-AMP reacts with the 20-hydroxyl (-OH) of
the terminal ribose at the 30-end of the tRNALeu to form Leu-
tRNALeu (ref. 3). LeuRSs are also composed of a number of
additional domains involved in binding tRNALeu or in
proofreading activities4–7. X-ray crystal structures have been
obtained for LeuRSs from both archaeal and bacterial origins in
complex with a number of substrates and substrate analogues,
including Leu5 and tRNALeu (refs 6,7), a reaction-intermediate
analogue of Leu-AMP5, and also substrate mimics of both post-
and pre-transfer editing reactions8. The range of different LeuRS
conformations visualized by these studies highlights the complex
interplay of these multi-domain enzymes with their substrates.
LeuRSs, and the other aaRSs, are essential enzymes that are
underutilized targets for the development of antibiotics9. The
most prominent inhibitor class that has been investigated are the
rationally designed stable analogues of aminoacyl-adenylates
(AA-AMPs)10–12, such as leucyl-adenylate sulphamoyl analogue
(Leu-AMS), which was used in X-ray crystallographic studies of
LeuRS to define the binding pocket of the reaction intermediate5.
Stable AA-AMP analogues have proven to be potent inhibitors of
a range of other aaRSs13,14. They are thought to act by competing
with the amino-acid and ATP substrates for binding to the
synthetic active site contained in the catalytic domain, thereby
inhibiting the amino-acid activation reaction and consequently
aminoacylation.
Agrocin 84 is a recently identified inhibitor of LeuRS15,16. The
antibiotic is produced by the biocontrol agent Agrobacterium
radiobacter strain K84 that is used worldwide to protect plants
against the economically important disease crown gall17. The
bacterial pathogen A. tumefaciens is the causative agent of the
disease and induces tumours into infected plants via the transfer
of oncogenic DNA18. Agrocin 84 specifically targets strains of
A. tumefaciens by acting as a molecular Trojan horse that mimics
a plant tumour-derived substrate to gain access into the
agrobacterial cell19,20. Once inside, agrocin 84 is processed into
a toxin, TM84, which we have shown to be a potent inhibitor of
the A. tumefaciens genome-encoded LeuRS (LeuRSAt)16. TM84
closely resembles the obligate reaction intermediate of LeuRSs,
Leu-AMP (Fig. 1b), but contains a relatively stable N-acyl
50-phosphoramidate bond instead of the labile phosphoanhydride
linkage.
We previously hypothesized that TM84 acts as a stable
analogue of Leu-AMP and inhibits LeuRS by binding to the
synthetic active site16. Surprisingly, we now show that TM84 is
different from Leu-AMP analogues, as it employs a unique tRNA-
dependent inhibition mechanism in which the 30-end of tRNALeu
is required to form an ‘aminoacylation-like’ conformation that
stabilizes the binding of the inhibitor in a ternary inhibition
complex. Our structure, together with a recently published
structure of an Escherichia coli LeuRS  tRNALeu  Leu-AMP
analogue21, reveal exciting new insights into the recognition of
tRNALeu by LeuRS during aminoacyl transfer, and molecular
details of how the enzyme catalyses the second stage of the
aminoacylation reaction.
Results
TM84 is a tight-binding inhibitor of tRNALeu aminoacylation.
To determine the mechanism by which TM84 inhibits LeuRSAt,
we examined inhibition of the leucylation reaction using an
in vitro transcribed substrate encoding the tRNALeu(UAA)
A. tumefaciens isoacceptor. Our results clearly show substantial
inhibition of the aminoacylation reaction at concentrations of
TM84 ([I]¼ 3 nM) similar to that of the LeuRSAt enzyme
([E]¼ 4 nM) (Fig. 1c). The stoichiometric levels of TM84 to
enzyme required to see inhibition strongly suggested that TM84 is
a tight-binding inhibitor of LeuRSAt, and therefore required the
use of non-Michaelis–Menten kinetic analysis of subsequent
inhibition assays to determine the true potency of the inhibitor22.
Tight-binding inhibitors often display a slow onset of
inhibition due to conformational changes of the enzyme on
inhibitor binding23. This behaviour is typically manifested as a
curvilinear appearance to enzyme initial rates that cannot be
adequately analysed using the standard discontinuous assays used
for aaRSs. To eliminate the potential complexity of slow binding
effects on our analysis, TM84 was pre-incubated with the enzyme
and tRNALeu before initiating the aminoacylation reaction. We
then plotted the fraction of the aminoacylation rate measured
against [TM84] and fit the resulting dose–response curve
(Fig. 1d) to the Morrison equation for tight-binding inhibitors.
The fit showed an apparent Ki (Kiapp) of 0.3±0.1 nM, which
suggests that TM84 behaves as a tight-binding inhibitor of
LeuRSAt (ref. 22).
TM84 weakly inhibits Leu-AMP formation in the absence of
tRNALeu. We previously hypothesized that TM84 competes with
Leu and ATP for binding to the synthetic active site16. To test
this, we examined if TM84 could inhibit activation of Leu by ATP
in a similar manner to Leu-AMS. We made use of the ATP/
pyrophosphate exchange reaction (ATP/PPi), which measures the
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Figure 1 | TM84 is a tight-binding inhibitor of the LeuRSAt
aminoacylation reaction. (a) Aminoacylation reaction of LeuRS.
(b) Comparison of Leu-AMP and TM84—differences in red. (c) Inhibition
of LeuRSAt (4 nM) aminoacylation reaction þ / TM84 (3 nM). Error bars
on the initial rate time points represent standard deviation, n¼ 3. (d) The
TM84 dose–response curve of LeuRSAt (4 nM) aminoacylation reaction
was fit to the Morrison equation for tight-binding inhibitors (equation (1)),
indicating a Ki app of 0.3±0.1 nM.
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and ATP substrates, through addition of excess [32P]-labelled
inorganic PPi that leads to formation of [g-32P] ATP via a back
reaction24,25. Thus, it is possible to observe the enzyme catalysing
multiple turnovers of the Leu activation reaction. As expected,
our results show that Leu-AMS is a potent inhibitor of the
LeuRSAt-catalysed ATP/PPi exchange reaction (Supplementary
Fig. S1). Surprisingly, TM84 did not potently inhibit amino-acid
activation (Fig. 2a). High concentrations of TM84 (limited by
availability of this natural product) were required to see even
partial inhibition (Fig. 2b).
A potential explanation of how TM84 can be a strong inhibitor
of the overall aminoacylation, yet not the Leu activation reaction,
could be a requirement for tRNALeu in the inhibition mechanism.
To test this, we examined if TM84 inhibition of the LeuRSAt
aminoacylation activity could be reduced using low
concentrations of tRNALeu substrate. However, the low
concentrations of tRNA required to see activity in these assays
made quantitation of Leu-tRNALeu difficult, even when sensitive
TLC-based assays were used. To circumvent this, we explored the
requirement for tRNALeu in the inhibition mechanism of TM84
by adding in vitro transcribed tRNALeu to the ATP/PPi-exchange
reaction. This approach has been used before for aaRS enzymes
such as glutaminyl-26 and glutamyl-tRNA synthetases27, which,
unlike LeuRSs, require tRNA for the activation reaction to
proceed. Importantly, in these experiments we used an active
tRNALeu concentration of 6.7 mM that had no effect on the initial
rate of ATP/PPi exchange for the LeuRSAt reaction (Fig. 2a). In
addition, negligible amounts of Leu-tRNALeu, the product of the
aminoacylation reaction, were detectable under these reaction
conditions ([LeuRSAt]¼ 1 nM (Supplementary Fig. S2)). Our
experiments were performed þ / tRNALeu and by varying the
[TM84]. The resulting dose–response data were analysed as
detailed previously28 and showed a greater than 4 orders of
magnitude increase in the inhibition of the amino-acid activation
reaction with tRNALeu compared to that without tRNALeu (IC50
TM84¼425mM and IC50 TM84  tRNA¼ 0.7±0.1 nM; see Fig. 2b).
These results were strongly suggestive that tRNALeu actively
participates in the inhibition mechanism of TM84 for LeuRSAt,
but also did not rule out that TM84 binds to an alternative site on
the enzyme.
Some tight-binding enzyme inhibitors form covalent bonds
with protein residues (or RNA substrates), leading to irreversible
interactions22,29. To determine if this was the case with the
interaction of TM84 with LeuRSAt, we pre-incubated LeuRSAt
with TM84 and tRNALeu and then added an RNase cocktail to
degrade the tRNA into mononucleotides. We then tested samples
that had both been incubated þ / RNase for activity in the
ATP/PPi exchange experiment. The presence of tRNA potently
inhibited the LeuRSAt Leu activation reaction, whereas RNAse
treatment completely restored activity in the presence of TM84
(Fig. 2c). This experiment demonstrates that TM84 binds
reversibly to LeuRSAt and also supports the idea that tRNA is
essential for the tight binding of TM84 to LeuRSAt.
tRNALeu increases the binding affinity of TM84 for LeuRSAt.
To gain further insights into the unusual ternary inhibitor
interaction, we employed isothermal calorimetry (ITC) to test the
effect of tRNALeu on the energetics of TM84 binding to LeuRSAt.
Initially, we examined the two separate binding reactions of
TM84 (Fig. 3a) and tRNALeu to LeuRSAt (Table 1). The two
isotherms obtained for binding of TM84 to LeuRSAt and tRNALeu
to LeuRSAt both fit to single-site binding models with stoichio-
metries close to 1, and with a calculated Kd TM84 of 152±20 nM
and a Kd tRNA of 84.9±6.1 nM. We then examined the ternary
equilibria after pre-incubation with tRNALeu (Fig. 3a,b). For these
experiments, tRNA was first pre-bound to the protein in the ratio
of 1.2:1. TM84 was then titrated into the protein–tRNA mixture
to obtain the LeuRS  tRNALeu TM84 complex. Surprisingly, the
isotherms of the ternary equilibrium exhibited distinct biphasic
forms that could not be fitted to a simple single-site model.
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Figure 2 | tRNALeu is required for reversible TM84 inhibition of leucine
activation. (a) TM84 inhibition of LeuRSAt (1 nM) ATP/PPi exchange
reaction þ / tRNALeu (6.7mM). Initial rate reaction conditions are
LeuRSAt only (D), LeuRSAt with 1mM TM84 (J), LeuRSAt with tRNALeu
(m), and LeuRSAt with tRNA
Leu and 50 nM TM84 (K). Error bars indicate
standard deviation, n¼ 3. (b) TM84 dose–response curves of LeuRSAt-
catalysed ATP/PPi-exchange reaction in the absence (J) and presence
(K) of tRNALeu. IC50 TM84425mM and IC50 TM84  tRNAo1 nM. (c) Effect of
RNase treatment on LeuRSAt  tRNALeu TM84 complex ATP/PPi exchange
activity. Reaction conditions examined were LeuRSAt with tRNA
Leu (m),
LeuRSAt with tRNA
Leu and 250nM TM84 (K), preformed
LeuRSAt  tRNALeu complex treated with RNase (&), and preformed
LeuRSAt  tRNALeu TM84 complex treated with RNase (B).
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two-site model with two TM84 binding sites with two different
affinities of 0.81±0.31 nM (Kd1) and 14.4±1.37 nM (Kd2).
Although a possible explanation for these results might be that
the presence of tRNA creates a second TM84 binding site on the
LeuRSAt  tRNA complex, this is not possible as the total stoi-
chiometry of binding in this case would be close to 2. Our data
reveal stoichiometric values for the two binding events, n1 and
n2, summing close to 1 (n1þ n2E1). Biphasic isotherms can be
observed in heterotropic ligand-binding interactions to
proteins that display co-operative ligand binding if one of the
ligands is present at subsaturating concentration30. However,
this possibility can be ruled out as the tRNA concentration
is saturating. Our results therefore suggest that, rather than
observing two independent sites for TM84 on one protein, we are
seeing the binding of TM84 to two distinct populations of
LeuRSAt  tRNALeu with two different affinities for TM84.
A mixed population of LeuRSAt  tRNALeu complexes could
originate in two ways. First, single-nucleotide resolution PAGE
analysis of the transcript shows B11% of tRNAs with an
additional nucleotide (Nþ 1) added to the 30-ends. This is a
known side reaction of T7 RNA polymerase when catalysing
in vitro transcription reactions31. Second, partially misfolded
species, perhaps owing to lack of tRNA modifications, are also
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Figure 3 | tRNA induces TM84 tight-binding and adopts the modified conformation. (a) ITC titration of TM84 into LeuRSAt. The top panel shows raw
thermogram and bottom panel shows the binding isotherm fitted to a single-site model (see Table 1 for thermodynamic values). (b) Titration of TM84 into
LeuRSAt  tRNALeu complex. Bottom panel isotherm fitted to a two-independent-sites model. (c) Fluorescent tRNApyrLeu probe sensitive to the environment
of the CCA 30-end. Pyrrolo-Cyt base (red) located at nucleotide Cyt75. (d) Fluorescence emission spectra for tRNApyrLeu (tRNA*) free or bound to
different LeuRSAt complexes.
Table 1 | Isothermal titration calorimetry data showing binding of TM84 and/or tRNALeu to LeuRSAt.
Complex Model Kd (nM) Stoichiometry DH (kcalmol 1) TDS (kcalmol 1) DG (kcalmol 1)
LeuRSAt TM84 One site 152±20 0.93±0.08  10.4±0.3 0.95±0.4 9.4±0.08










LeuRSAt  tRNALeu One site 84.9±6.1 0.93±0.01  16.2±0.6 6.4±0.6  9.7±0.04
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be aminoacylated. In our case, only B50% of the tRNALeu
transcripts could be aminoacylated. Interestingly, binding of
tRNALeu to LeuRSAt produces a monophasic isotherm, suggesting
that the different tRNALeu species have similar affinities for the
enzyme that are indistinguishable from each other in the
isotherm. However, the subsequent binding of TM84 can
discriminate between the different LeuRSAt  tRNALeu
complexes, giving rise to biphasic isotherms reflecting different
binding events.
A comparison of the isotherms indicates that TM84 is a
relatively weak binder (Kd¼ 152±20 nM) to LeuRSAt alone
compared to binding to the enzyme pre-incubated with tRNALeu
(Kd¼ 0.81±0.31 nM high-affinity complex). The analysis
indicates that binding of TM84 is enhanced up to B200-fold in
the presence of tRNA. If two different LeuRSAt  tRNALeu
complexes are considered, heterotropic interaction constants of
190 and 11 for each complex can be estimated from the ITC
experiments30, which correspond to cooperativity Gibbs energies
of  3.1 and  1.4 kcalmol 1, respectively. Therefore, tRNALeu
binding to LeuRS adds a 30% increase to the binding Gibbs
energy for TM84. These findings are consistent with the results
from our kinetics experiments that implicate tRNALeu in the
inhibition mechanism of TM84.
TM84 binding to LeuRS . tRNA alters CCA 30-end conforma-
tion. The ITC results suggest that catalytically active tRNA and its
CCA 30-end may have an important role in facilitating the tight
binding of TM84 in the ternary inhibition complex. To test this,
we constructed a tRNA incorporating a fluorescent probe that is
sensitive to the conformation and environment of the 30-terminal
nucleotides. We exchanged the penultimate Cyt75 residue of
tRNALeu with a fluorescent pyrrolo-cytidine nucleotide (Fig. 3c).
This approach was used to monitor the conformation of the CCA
30-end of tRNACys interacting with cysteinyl-tRNA synthetase32.
By monitoring the fluorescence from this probe, we expected to
see a significant change in the spectrum when the
LeuRS  tRNApyrLeu complex was bound to TM84 or not.
E. coli CCA nucleotidyl transferase was used to catalyse the
addition of ATP and pyrCTP onto a truncated in vitro
transcribed tRNALeu(UAA) sequence from A. tumefaciens.
Importantly, the fluorescently labelled tRNApyrLeu was a
substrate (if somewhat reduced in activity) for the
aminoacylation reaction of LeuRSAt, indicating that the probe
did not disrupt the interaction of the CCA 30-end with the
enzyme. We examined the fluorescence spectra of tRNApyrLeu
alone, and in the presence of LeuRSAtþ /TM84 or Leu-AMS.
The emission fluorescence spectrum of tRNALeu bound to
LeuRSAt shows a lmax of 456 nm (Fig. 3d). Addition of Leu-
AMS to the protein–tRNA complex produces a fluorescence
spectrum with similar intensity. However, addition of TM84 both
increases the fluorescence intensity (B1.5-fold) and shifts the
lmax by 5 nm. This unique TM84-induced spectral signal suggests
that the toxin causes a rearrangement of the CCA 30-end of the
tRNA when bound to the LeuRS enzyme. Interestingly, this
conformation of the CCA 30-end of the tRNA does not appear to
be substantially populated in the LeuRS  tRNApyrLeu  Leu-AMS
ternary complex.
Structure of the LeuRS . tRNALeu .TM84 inhibition complex.
To understand how TM84 binds to LeuRS and gain structural
insights into the role of tRNALeu in the unusual LeuRS inhibitory
properties of TM84, we crystallized LeuRS in complex with
tRNALeu and TM84. We used recombinant E. coli LeuRS
(LeuRSEc) and in vitro transcribed E. coli tRNALeu(UAA) iso-
acceptor substrates, which have recently been shown to produce
high diffraction-quality crystals21. Importantly, LeuRSEc shares
46% sequence identity with, and has similar domain architecture
to, LeuRSAt (Fig. 4a). LeuRSEc has similar steady-state kinetic
properties to that of LeuRSAt (Supplementary Table S1) and
aminoacylation by LeuRSEc is potently inhibited by TM84
(Supplementary Fig. S3). The crystal structure of the
LeuRSEc  tRNALeu TM84 complex was solved by molecular
replacement using the core of the complex formed by Thermus
thermophilus LeuRS (LeuRSTt) with tRNALeu 6, followed by
building of the insertion domains. The model was refined to a
final R-factor of 18.2% (R-free¼ 23.6%) at a final resolution of
2.4 Å (Fig. 4b; Table 2). The asymmetric unit contained two
molecules of the ternary complex LeuRS  tRNALeu TM84, one
with slightly higher B-factors than the other.
The overall structure of the LeuRSEc  tRNALeu TM84 complex
(Fig. 4b) is very different from the previously described editing
conformation of bacterial LeuRS6. Remarkably, it shows that the
tRNALeu acceptor stem is present in an ‘aminoacylation-like’
conformation, with the CCA 30-end penetrating into the synthetic
active site of LeuRSEc where TM84 is bound (Fig. 4b,c;
Supplementary Figs. S4, S5a). This suggests that TM84 causes
inhibition of LeuRSs by resembling a stable form of Leu-AMP
and thus prevents binding of the Leu and ATP substrates16. This
finding also weakens an alternative hypothesis that proposes that
the unusual inhibitory properties of TM84 are caused by the
inhibitor binding to an alternative site on the enzyme other than
the synthetic active site8,33. The most striking feature of the TM84
ternary structure is the pronounced movement of the highly
conserved KMSKS loop across the active site of the enzyme when
compared with previous LeuRSTt structures bound to adenylate
analogues5,8 or tRNA6 (Fig. 4d). The synthetic active site where
TM84 is located is almost completely covered, encapsulating
the ligand and presumably decreasing the dissociation rate of
the inhibitor from the enzyme. The closed conformation of the
KMSKS loop allows new protein–tRNA interactions that stabilize
the aminoacylation conformation of the tRNA, notably the
hydrogen bonds between the side chain of Lys619 and both
the base of Cyt75 and phosphate of Gua71 (Supplementary
Fig. S5a,b). Indeed, the structure shows that substantial
re-ordering of the active site is mandatory for TM84 to form its
‘aminoacylation-like’ ternary complex. Interestingly, this is a
property found in slow, tight-binding enzyme inhibitors23.
To identify key interactions in the LeuRS ternary complex that
may be responsible for the tRNA-dependence of TM84 binding,
we made comparisons with a structure of LeuRSEc 
tRNALeu  Leu-AMS captured in the functional aminoacylation
conformation 21. Leu-AMS, unlike TM84, does not show tRNA-
dependent binding to LeuRS and as a consequence the tRNA
could occupy more than one conformation on the enzyme in
solution, an observation that is in accordance with our
fluorescence data (Fig. 3d). Interestingly, the average B factors
obtained from both structures do not reveal significant differences
in the overall mobility of the two proteins in the crystal nor when
individual B factors for domains are compared. A close
comparison between the binding mode of TM84 (Fig. 4c) and
Leu-AMS in their respective LeuRSEc  tRNALeu ‘aminoacylation-
like’ ternary complexes identifies a number of shared interactions
between both ligands (His52, Phe493, Gly530, Glu532, His533,
His537, Gln566, Val569 and Met620), but also reveals key
variations between the binding mode exhibited by the two ligands
(Fig. 5a–c) that could explain their fundamental difference in
tRNA-dependency. The chemical structures of TM84 and Leu-
AMS are different, which is reflected in the differential binding
and inhibition behaviours exhibited by the two molecules. In
TM84, the Leu side-chain is replaced by a substituted methyl
pentanamide with an OH group (C2-OH) replacing the a-amino
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group and an additional OH group on the side-chain (C3-OH)
(Fig. 1b). The C2-OH of the methyl pentanamide group of
TM84 forms a hydrogen bond with Asp80, mimicking the
interaction with the a-amino group as in the Leu-AMS bound
protein. However, the main chain carbonyl oxygen of Leu41
hydrogen bonds to the C3-OH of TM84 (Fig. 5a), whereas in the
Leu-AMS complex, it only hydrogen bonds with the a-amino
group (Fig. 5b). TM84 also contains a 3-deoxyarabinose sugar
ring substituting for the ribose found in Leu-AMP/Leu-AMS. In
the Leu-AMS-bound structure, the ribose 20-OH and 30-OH
groups, each make a hydrogen bond with active site residue
Gly530 (Fig. 5b). However, the loss of the cis-diol from the
TM84 sugar results in only a single hydrogen bond between its
20-OH group and Gly530 that extends above the plane of the
sugar ring (Fig. 5a). Perhaps the most striking and intriguing
difference between the two ternary complexes is in the ribose
pucker of the terminal adenosine (Ade76). In the Leu-AMS
functional aminoacylation state, this ribose is in a C20-exo
conformation, allowing the 20-OH to point towards the
carbonyl-carbon of Leu-AMS (Fig. 5b,c) as would be expected
prior to the transfer step in the aminoacylation reaction21. In
the TM84 complex, the Ade76 ribose is in an unexpected C20-
endo conformation, resulting in the 20-OH pointing away from
the carbonyl-carbon and instead forming a hydrogen bond to a
nearby water molecule that in turn hydrogen bonds to Asp80
and Ser496 (Fig. 5a,c). The altered position of the 30-OH allows
it to make a direct hydrogen bond to the C2-OH of TM84. This
direct interaction between tRNALeu and TM84 may play an
additional role in stabilizing the ternary inhibition complex.
Importantly, there is also a significant difference between the
KMSKS loop conformation for the two ligands. Whereas in the
Leu-AMS ternary complex the second Lys of the K619MSK622S
loop (Lys622) points away from the active site (Fig. 5b), in the
TM84 complex Lys622 points right into the active site and
interacts with a non-bridging oxygen of the negatively charged
N-acyl phosphate group of TM84 (Fig. 5a; Supplementary Fig.
S5b). The positioning of Lys622 is also a contributing factor in
the reduced solvent accessibility of TM84 when bound to the
LeuRSEc (20.6 Å2) compared to Leu-AMS (44.2 Å2). Several
factors may contribute to the different conformations exhibited
by Lys622 in the two structures. First, the insertion of positively
charged Lys622 into the active site is electrostatically favoured
both by the presence of the charged N-acyl phosphate group and
by the absence of the a-amino group in the case of TM84. In
contrast, for Leu-AMS, the sulphate is uncharged. Second, the
particular C20-endo ribose pucker of Ade76 in the TM84
complex avoids potential steric hindrance of Lys622 entering the
site, which would be the case with the functional C20-exo
conformation. Interestingly, His52, the second histidine residue
of the H49IGH52 catalytic motif, makes an interaction with the
other non-bridging oxygen of the phosphate moiety of TM84
(Fig. 4c). Although the ionic interaction between Lys622 and the
a-phosphate of TM84 is not seen in other LeuRS structures
bound to the adenylate analogue (but it remains to be seen what
would happen with the true negatively charged Leu-AMP), an
equivalent interaction was found in a GlnRS  tRNAGln Gln-
AMS ‘aminoacylation’ structure10. However, the conformation
of the KMSKS loop in this structure does not close so fully over
the synthetic active site as in the LeuRS ternary complexes. The
observed position of the second lysine of the KMSKS catalytic
peptide in the TM84 complex more resembles the conformation
expected for the amino-acid activation reaction, as this residue
is known to have an important role in both catalysis of




























Figure 4 | Structure of the LeuRSEc . tRNA
Leu .TM84 inhibition complex. (a) Domain structure of LeuRSEc. (b) Structure of LeuRSEc  tRNALeu TM84
complex in ‘aminoacylation-like’ conformation. Domains coloured and labelled, tRNALeu (blue) with Ade76 and TM84 depicted with stick bonds in
synthetic active site. (c) Active site interactions with TM84. (d) Encapsulation of TM84 (space filling model—pink) in synthetic active site. LeuRSEc protein
surface—grey and tRNALeu—blue.
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Discussion
Our biophysical and biochemical analyses elucidate a new tRNA-
dependent LeuRS inhibition mechanism for TM84, which clearly
distinguishes it from Leu-AMS. The crystal structure of the TM84
ternary complex, however, only reveals subtle differences. The
binding of TM84 to the LeuRSAt active site in the absence of
tRNA is considerably weaker than that observed for Leu-AMS. A
number of interactions found in Leu-AMS-bound structures5,21
that are absent when TM84 is bound (Figs. 4c, 5a,b) may explain
the reduced affinity of TM84 for LeuRSAt in the absence of tRNA.
These include loss of hydrogen bonds to the sugar moiety of the
nucleotide and loss of a potential ionic interaction with Leu-AMS
when its amino group is replaced with a hydroxyl in TM84. The
crystal structure also reveals three additional interactions that are
formed in the presence of tRNA: Lys619 to Cyt75; Lys622 to the
phosphate of TM84; and Ade76 to TM84 (Supplementary Fig.
S5b). We hypothesize that absence of tRNA and concomitant loss
of two of these interactions lead to increased KMSKS loop
mobility, and destabilization of the Lys622 interaction with
TM84.
The role of tRNA and the KMSKS loop in binding TM84 also
raises kinetic questions about the exact order of binding events.
TM84 has to bind to an open active site prior to the positioning of
the CCA 30-end in the final closed ternary complex, leading to
decreased dissociation of TM84 (slow koff rate). What is not clear,
is how rapidly TM84 binds to the open active site (kon); how
tRNA might affect this initial binding event; or whether the
KMSKS loop binds to TM84 independently of the CCA 30-end or
not. Pre-steady-state kinetic analysis is required to determine the
precise order of these events.
Why would nature evolve a Trojan Horse LeuRS inhibitor16
with a tRNA-dependent inhibition mechanism? Perhaps when
LeuRSAt is inhibited, substrate concentrations would be expected
to rise in agrobacterial cells. Under these conditions, a simple
LeuRS competitive inhibitor might have decreased toxicity,
whereas the higher concentrations of deacylated tRNALeu would
increase the affinity of TM84 for the enzyme. Whatever the
reason, this study provides insight into a novel tRNA-dependent
inhibitor of LeuRS with potential ramifications for rational
antibiotic design.
Methods
Protein expression and purification. LeuRSAt was expressed in E. coli BL21 (DE3)
RIL codon plus cells containing the pET-21b plasmid encoding LeuRSAt with a
carboxy-terminal 6X-histidine tag (the leuSAt gene had been subcloned in to pET-
21b using NdeI and XhoI restriction sites)16. Cells were grown in Luria broth at
37 1C, with appropriate antibiotics, to an optical density of 0.3–0.4 (measured at
A600) before induction with 1mM isopropyl-B-D-thiogalactopyranoside. The cells
were grown for an additional 3–4 h at 24 1C before harvesting by centrifugation at
5,400 g for 10min. Cells were lysed by sonication in standard Qiagen lysis buffer.
The soluble His-tagged LeuRSAt protein was purified using Ni-NTA agarose
(Qiagen) as detailed by the manufacturer. The protein was further purified by
FPLC using a Mono-Q column and a gradient of 20mM NaCl to 500mM NaCl in
Tris–HCl buffer (pH 8.0). The purified protein was confirmed to be 495% pure
using SDS–polyacrylamide gel electrophoresis. Active LeuRSAt protein
concentration for kinetic assays was determined by active site titration (see below).
LeuRSEc used for structural studies was expressed in E. coli BL21 cells containing
pET-15b plasmid encoding LeuRSEc with an amino-terminal 6X-histidine tag
(MGSSHHHHHHSSGLVPRGSH) under similar conditions21.
Table 2 | Data collection and refinement statistics.




a, b, c (Å) 158.58, 68.19, 226.22
a, b, g (1) 901, 105.53, 901
Solvent content (%) 53.5
Beamline ESRF ID14-4
Wavelength (Å) 0.9395
Detector ADSC quantum Q315r
Resolution range of data (last shell)
(Å)
43.59–2.4 (2.40–2.50)
Completeness (last shell) (%) 93.3 (65.1)
R-sym (last shell) 0.104 (0.435)
I/sI (last shell) 10.2 (1.8)
Redundancy (last shell) 3.91 (1.7)
Refinement
No. of reflections used in
refinement work (free)
80,975 (4,280)
R-factor (last shell) 0.187 (0.343)
R-free (last shell) 0.238 (0.389)




Solvent 369 water, 7 Mg2þ





Disallowed regions 0.2 (4 outliers/1,716 residues)
R.m.s. deviations
Bond distances (Å) 0.010



























Figure 5 | Comparison of TM84 and Leu-AMS bound in LeuRSEc ternary
complexes. (a) TM84 (pink) binding in the synthetic active site showing
interactions with the KMSKS loop (gold) and the terminal tRNA Ade76
(blue). The ribose of the adenosine is in the C20-endo conformation. Water
molecule depicted as a red sphere. (b) Leu-AMS (grey) in its respective
ternary complex. The ribose of the adenosine in this structure is in the
C20-exo conformation. (c) Superimposition of the two ligands in their
respective ternary complexes.
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TM84 purification. Agrocin 84 (purified as detailed previously16) was incubated in
sodium phosphate buffer (pH 7.0) at 100 1C for 15min and the liberated TM84
toxin was separated from other reaction products by reverse-phase high-
performance liquid chromatography. The concentration of purified TM84 was
determined using an extinction coefficient (e260 nm) of 0.0154M 1 cm 1.
tRNALeu transcription. Plasmids encoding tRNALeu(UAA) isoacceptor sequences
from A. tumefaciens C58 or E. coli in front of T7 polymerase promoter sequences
were purified from E. coli DH5-a cells before digestion overnight at 60 1C with
BstNI restriction enzyme to linearize the plasmid DNA. The transcription reaction
was performed using template DNA (450 mg), 9 mM T7 RNA polymerase35,
1Uml 1 RNAse inhibitor, 40mM Tris-HCl (pH 8.0), 25mM MgCl2, 40mM
DTT, 0.1% Triton X-100, 1mM spermidine and 2mM rNTPs. The reaction mix
was incubated at 37 1C overnight before quenching with 50mM EDTA followed by
DNase I digestion for 1 h to remove template DNA. Phenol–chloroform extraction
(pH 5.2) followed by ethanol precipitation (using 0.3M sodium acetate) isolated
the tRNA from the reaction. The precipitated tRNA was gel purified on a 12%
denaturing polyacrylamide gel electrophoresis (19:1), 8M urea gel and 1 Tris–
borate EDTA buffer (pH 8.3). After gel extraction, elution and ethanol
precipitation, the purified tRNALeu(UAA) was refolded by denaturing at 95 1C for
1min, followed by addition of 1mM MgCl2, and gradually cooled to 28 1C for 1 h.
The concentration of refolded tRNALeu was determined using a theoretical
extinction coefficient (e260) of 531,500M 1 cm 1 modified by a factor of 1.34 to
account for the hypochromic effect of tRNA folding on absorbance.
Active site titration assay. The concentration of active LeuRS enzyme for kinetic
assays was determined by active site titration as described previously25. The
reaction buffer contained 50mM HEPES buffer (pH 7.4), 20mM KCl, 10mM
MgCl2, 10mM b-mercaptoethanol (b-ME), 1mM L-Leu, 5 mg/ml inorganic
pyrophophatase, 5 mM ATP, 4 mCi [g-32P] ATP and purified recombinant LeuRS
enzymes ranging in total protein concentration from 1 to 2 mM (determined by
Biorad Protein assay). The reaction was carried out at 28 1C and 5 ml time point
aliquots collected. The assay was performed in triplicate and the active enzyme
concentration was determined by measuring the amplitude of the burst phase of
Leu-AMP formation24,25.
ATP/PPi exchange assay. The ATP/PPi exchange assays were performed as
detailed earlier25. Reaction mixtures containing 50mM HEPES buffer (pH 7.4),
20mM KCl, 10mM MgCl2, 500mM L-Leu, 4mM ATP, 1mM tetrasodium
pyrophosphate (NaPPi), 10 mCimmol 1 [32P] NaPPi, 1 mM bovine serum albumin
and LeuRSAt (1–2 nM) were incubated at 28 1C. LeuRSAt enzyme was pre-
incubated for 1 h with inhibitor þ / tRNALeu (6.7mM) in appropriate
experiments and the reactions were initiated by addition of 4mM ATP and
incubated at 28 1C (LeuRSAt) or 37 1C (LeuRSEc). Five-microlitre aliquots for each
time point were collected, acid quenched and processed25. The amount of [32P]-PPi
incorporation into ATP was measured by liquid scintillation counting.
Aminoacylation assay. The 40-ml leucylation reaction mixtures contained 50mM
HEPES (pH 7.4), 20mM KCl, 25mM MgCl2, 25mM b-ME, 4mM ATP, 500mM
[3,4,5-3H] L-Leu (20 mCimmol 1), 5 mg/ml inorganic pyrophosphatase and
13.4 mM of active in vitro transcribed tRNALeu (50% tRNALeu(UAA) is active based
on tRNA charging at saturating enzyme and substrate concentrations). Reactions
were initiated with 1–8 nM of active LeuRS enzyme that had been pre-incubated
for 1 h with the tRNALeu substrate þ / inhibitor. Reactions were incubated at
28 1C (LeuRSAt) or 37 1C (LeuRSEc). Five-microlitre aliquots of the reaction mix
were spotted on 5% trichloroacetic acid (TCA) pre-soaked filter pads, washed twice
with 5% TCA and then with 70% ethanol at 4 1C. The pads were dried and
quantified using scintillation counting. Initial rates (within the first 10–15% part of
the reaction) were obtained and an average rate from three individual data sets was
used to plot the dose–response curve, which was fit to a standard form of the
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Steady-state fluorescence. The penultimate base of the appropriate tRNA-
Leu(UAA) isoacceptor was labelled with a pyrrolo-cytidine fluorophore. To achieve
labelling, E. coli tRNA nucleotidyl transferase enzyme was incubated with a
truncated in vitro tRNA transcript and pyrrolo-CTP (Trilink Biotechnologies) and
ATP as outlined previously32. Fluorescence experiments were performed in buffer
containing 50mM HEPES (pH 7.4), 20mM KCl, 10mM MgCl2 and 10mM b-ME
at 28 1C. Briefly, 0.2 mM pyrrolo-C labelled fluorescent tRNALeu(UAA) isoacceptor
was added to 1 mM LeuRSAt, and 2.5 mM TM84 or Leu-AMS. The fluorescence
spectra were collected on a Horiba Fluoromax-2 fluorimeter. The excitation
wavelength was 352 nm and emission was measured between 390–600 nm.
Excitation and emission slit widths were both 5 nm. The spectra were analysed with
Datamax software and corrected with appropriate blanks to obtain the final spectra.
Isothermal titration calorimetry. TM84 interactions with LeuRSAt were explored
using a VP-ITC and an Auto-ITC200 microcalorimeter (MicroCal/GE Healthcare).
All solutions were prepared in buffer containing 50mM HEPES (pH 7.4), 20mM
KCl, 10mM MgCl2 and 1mM b-ME. For thermodynamic experiments, LeuRSAt
active protein concentration was determined using ITC titration of a tight-binding
ligand (Leu-AMS) to LeuRSAt as detailed elsewhere36. LeuRSAt (active protein
concentrations ranging from 4 to 8 mM) was placed in the sample cell and the
ligand (at a concentration 10-fold higher than that of the protein) was placed in the
syringe. In the ternary titrations, tRNALeu was added to LeuRS in the cell at a 1:1.2
molar ratio. Titrations were carried out at pH 7.4 and 28 1C. The injection volume
was 5–15 ml and the time between injections was 180–240 s. The data were analysed
using Origin for ITC software (version 7), and fitted to a one-site or a two-site
binding model (due to mixing artefacts, the heat associated with the first peak was
excluded from the data analysis). Binding affinity (Kd), stoichiometry (N) and
enthalpy (DH) for each complex were determined. The c-values (¼ [Ptotal]Ka) in
our experiments varied from 4 to 900, well within the suggested range of 1–1,000
(ref. 37).
Crystallization and X-ray data collection. To crystallize the LeuRSEc 
tRNALeu TM84 complex, a 2-ml aliquot of the solution containing the complex
was mixed with 2 ml of a crystallization solution and then equilibrated by hanging-
drop vapour diffusion against 500ml of reservoir solution. Crystals appeared at
273 K within 4–5 days in 0.1M Bis-TRIS at pH 5.5 and 23–25% PEG 3350.
For data collection, crystals were flash-cooled directly in liquid nitrogen.
Diffraction data were collected at 100 K at the European Synchrotron Radiation
Facility on beamline ID14-EH4 (ESRF, Grenoble, France). Crystals were of space-
group C2 with two molecules of complex per asymmetric unit. Data sets were
integrated and scaled using the XDS suite38. Subsequent data analysis was
performed with the CCP4 suite.
Structure determination and refinement. The structure was solved by molecular
replacement (PHASER39) using the core of the protein from the LeuRSEc editing
complex (1–223, 416–568 and 795–860 residues21. The resulting model was used to
search for the core of the tRNA (bases 5–79) and to manually build the external
flexible domains using COOT40. The Zn domain (158–189), not visible in the
LeuRSEc editing complex, was built using the analogous T. thermophilus LeuRS
structure as a guide. Models were refined by rigid-body refinement, followed by
isotropic B-factor refinement using REFMAC5 with translation libration screw-
motion41. In the resultant 2m|Fo|D|Fc| and m|Fo|D|Fc| maps, we clearly found
both tRNA and TM84 electron densities. The crystallographic data collection and
final refinement statistics are presented in Table 1. Several hydrated magnesium
ions are observed within the tRNAs.
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